Good Manufacturing Practices (GMP) is the key to assuring quality of pharmaceutical products. To safeguard public use of pharmaceutical products, mandatory GMP implementation and compliance by all manufacturers was announced in 1982 by the Department of Health, Taiwan, and is kept up-to-date with global new quality concepts and development. In response to the global advancing of GMP standards and in an effort to continue to enhance, Taiwan Food and Drug Administration (TFDA) applied for the membership of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), which was accepted and as of 1 January 2013, ahead of Japan and Korea, become one of the participating authorities. Then within two years by 31 December 2014, all medicinal products manufacturers are in compliance with the more stringent PIC/S GMP standards. Taiwan has evolved into a new era of which the current standard is improved and harmonized with the global standards, and the public benefits from the quality of medicinal products similar to those in the advance countries. Due regard to public health and safeguard in a comprehensive manner, Taiwan continues to implement measures for quality assurance in respect of product life cycle management. This will include promoting GMP for Active Pharmaceutical Ingredients (API) and the Good Distribution Practice (GDP),complementing the scope of quality from the source to the distribution. As such, public safety and medicinal product quality is protected, across-the-board.